[{"address1": "1007 North Orange Street", "address2": "4th Floor", "city": "Wilmington", "state": "DE", "zip": "19802", "country": "United States", "phone": "857-444-0553", "website": "https://www.ayalapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Ruth  Ben Yakar Ph.D.", "age": 52, "title": "Chief Exec. Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stela  Gangrenovitch Ph.D.", "title": "Co-Founder, Chief Scientist Officer and Director", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Gengrinovitch LLB", "title": "Co-Founder, Chief Financial Officer and Director", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7647, "open": 0.799, "dayLow": 0.6375, "dayHigh": 0.80838, "regularMarketPreviousClose": 0.7647, "regularMarketOpen": 0.799, "regularMarketDayLow": 0.6375, "regularMarketDayHigh": 0.80838, "forwardPE": -1.0273973, "volume": 29186, "regularMarketVolume": 29186, "averageVolume": 25881, "averageVolume10days": 14148, "averageDailyVolume10Day": 14148, "bidSize": 3000, "askSize": 1000, "marketCap": 31975050, "fiftyTwoWeekLow": 0.5036, "fiftyTwoWeekHigh": 1.95, "fiftyDayAverage": 0.7233028, "twoHundredDayAverage": 0.83493274, "currency": "USD", "sharesOutstanding": 42633400, "sharesShort": 80341, "sharesShortPriorMonth": 74009, "sharesShortPreviousMonthDate": 1671062400, "dateShortInterest": 1673568000, "sharesPercentSharesOut": 0.0054, "heldPercentInsiders": 0.00017999999, "heldPercentInstitutions": 0.16648, "shortRatio": 1.57, "shortPercentOfFloat": 0.0135, "impliedSharesOutstanding": 46155000, "bookValue": 0.211, "priceToBook": 3.5545025, "trailingEps": -2.51, "forwardEps": -0.73, "52WeekChange": 0.48927724, "SandP52WeekChange": 0.29612947, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ADXS", "underlyingSymbol": "ADXS", "shortName": "Advaxis, Inc.", "longName": "Ayala Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1588944600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "64ddc3fb-93a1-3fcf-bd77-6cb2e777109e", "messageBoardId": "finmb_943010", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.75, "recommendationMean": 3.0, "recommendationKey": "hold", "financialCurrency": "USD", "trailingPegRatio": null}]